According to Gram Research analysis, reducing the LIPA protein in immune cells dramatically decreases atherosclerosis development in mice prone to heart disease. In a recent study, mice with reduced or absent LIPA developed significantly less arterial plaque and fewer foam cells—the cholesterol-filled immune cells that accumulate in plaques—even when eating a high-fat diet. This discovery suggests LIPA in macrophages could become a new therapeutic target for preventing heart disease.
Scientists discovered that a protein called LIPA, found mainly in immune cells called macrophages, plays a surprising role in heart disease development. When researchers reduced LIPA levels in mice prone to heart disease, the animals developed less plaque buildup in their arteries—the main problem in atherosclerosis. This discovery suggests that blocking LIPA in immune cells might become a new way to prevent or treat heart disease. The findings are important because LIPA has long been linked to heart disease risk in humans, but doctors didn’t understand exactly how it worked.
Key Statistics
A 2026 research article in the Journal of Lipid Research found that mice with reduced LIPA expression developed significantly attenuated atherosclerosis compared to controls, with protection confirmed through bone marrow transplant experiments showing the effect originated from immune cells.
In laboratory studies, macrophages completely lacking LIPA showed diminished lipid uptake and reduced CD36 expression—a key cholesterol-entry protein—with both effects reversed when LIPA was restored to the cells.
Mice with heterozygous LIPA deficiency (one functional copy) showed protection against atherosclerosis without developing the liver enlargement and increased immune cell production seen in completely LIPA-deficient mice.
The Quick Take
- What they studied: How a protein called LIPA in immune cells affects the development of atherosclerosis (plaque buildup in arteries that leads to heart disease)
- Who participated: Laboratory mice genetically modified to develop heart disease, with different levels of the LIPA protein. Researchers also studied immune cells in test tubes to understand the mechanisms.
- Key finding: Mice with reduced or missing LIPA developed significantly less arterial plaque and fewer foam cells (damaged immune cells that accumulate in plaques) compared to control mice, even when eating a high-fat diet.
- What it means for you: This research suggests that reducing LIPA activity in immune cells could potentially prevent or slow heart disease progression. However, this is early-stage research in animals, and human studies are needed before any new treatments could be developed.
The Research Details
Researchers created special laboratory mice that lacked the LIPA protein or had reduced amounts of it, combined with genetic changes that make them prone to heart disease. They fed these mice a high-fat diet to trigger atherosclerosis development, then compared how much plaque formed in their arteries compared to normal mice. The team also performed bone marrow transplants, moving immune cells from LIPA-deficient mice into regular disease-prone mice to test whether the protection came specifically from immune cells. Additionally, they studied isolated immune cells in laboratory dishes to understand the exact mechanisms.
This approach is important because it isolates the specific role of LIPA in immune cells rather than in the liver, where LIPA is also produced. Previous research couldn’t clearly separate these effects. By using genetic tools and cell transplants, the researchers proved that LIPA in macrophages—not in the liver—drives the heart disease process. This precision helps identify a more targeted treatment approach.
The study used multiple complementary approaches (genetic models, bone marrow transplants, cell culture, and advanced genetic analysis called single-cell RNA sequencing) that all pointed to the same conclusion, strengthening confidence in the findings. The research was published in the Journal of Lipid Research, a respected peer-reviewed journal. However, these are animal studies, so results may not directly translate to humans.
What the Results Show
Mice with reduced or completely absent LIPA developed dramatically less atherosclerosis compared to control mice, even when fed a high-fat diet. This protection appeared in both mice with one functional copy of LIPA (heterozygous) and mice with no functional copies (homozygous). The key mechanism was a reduction in foam cells—immune cells that become bloated with cholesterol and accumulate in arterial plaques. When researchers transplanted bone marrow from LIPA-deficient mice into disease-prone mice, the recipients also developed less atherosclerosis, proving the protection came from immune cells rather than other tissues. In laboratory studies, macrophages lacking LIPA took up less cholesterol and had lower levels of a protein called CD36, which acts like a door allowing cholesterol to enter cells.
Mice completely lacking LIPA developed enlarged livers and spleens (hepatosplenomegaly) and showed increased production of immune cells in bone marrow when fed a high-fat diet, similar to what happens in humans with LIPA deficiency. However, reduced LIPA in heterozygous mice did not cause these liver problems or affect normal immune cell development, suggesting that complete loss of LIPA has broader effects than partial reduction. Advanced genetic analysis showed that partial LIPA reduction primarily worked by lowering CD36 expression, while complete absence affected both immune cell development and CD36 levels.
This research resolves a long-standing puzzle in cardiovascular science. LIPA has been identified as one of the earliest and most important genetic risk factors for heart disease in humans, but previous studies using complete LIPA knockout mice produced confusing results. This new work clarifies that the problem is specifically in macrophages, not in the liver where LIPA is primarily made. The findings align with observations in humans carrying atherosclerosis-risk versions of the LIPA gene, who show high LIPA levels in immune cells but low levels in liver and blood.
This research was conducted entirely in laboratory mice and test-tube cell cultures. Mice don’t develop heart disease exactly like humans do, so results may not translate directly. The study doesn’t test any actual drug treatments—it only shows what happens when LIPA is genetically removed. Human studies would be needed to determine whether blocking LIPA is safe and effective. Additionally, the research doesn’t fully explain all the ways LIPA affects immune cell behavior, only identifying CD36 as one important mechanism.
The Bottom Line
Based on this research, LIPA emerges as a promising target for developing new heart disease treatments. The evidence is strong that reducing LIPA in immune cells protects against atherosclerosis in animal models. However, confidence in human application is moderate because animal studies don’t always translate to people. Any clinical development would require careful testing to ensure safety, particularly given that complete LIPA loss causes liver problems.
This research is most relevant to people at high genetic risk for early heart disease, particularly those carrying LIPA risk variants. Cardiologists and researchers developing new heart disease treatments should pay attention. People with existing heart disease may eventually benefit if this leads to new drugs. This research is not yet actionable for the general public, as no treatments based on these findings are currently available.
This is fundamental research identifying a new drug target. Typically, 5-10 years of additional research would be needed to develop and test a drug that safely blocks LIPA in humans. If successful, clinical trials could take another 5-7 years. Realistic timeline for a potential new treatment: 10-15 years.
Frequently Asked Questions
What is LIPA and why does it matter for heart disease?
LIPA is a protein found mainly in immune cells called macrophages. It’s one of the earliest genetic factors linked to heart disease risk in humans. New research shows LIPA helps immune cells absorb cholesterol, contributing to plaque buildup in arteries. Reducing LIPA could prevent this process.
Can blocking LIPA prevent atherosclerosis in humans?
This research shows blocking LIPA prevents atherosclerosis in mice, but human studies haven’t been done yet. The findings are promising enough to warrant further research, but any new treatment would require years of testing for safety and effectiveness before becoming available.
How does LIPA affect foam cells and plaque buildup?
LIPA helps macrophages absorb cholesterol through a protein called CD36. When LIPA is reduced, macrophages take up less cholesterol and don’t become foam cells. Fewer foam cells means less plaque accumulation in arteries, reducing atherosclerosis development.
Is it safe to have low LIPA levels?
Mice with partial LIPA reduction showed no harmful effects on liver function or immune cell development. However, complete LIPA absence caused liver enlargement. This suggests partial reduction might be safe, but human studies are needed to confirm safety in people.
When will LIPA-targeting drugs be available?
This is early-stage research. Typically, 10-15 years of development and testing would be needed before a LIPA-targeting drug could reach patients. Researchers must first develop candidate drugs, then conduct animal and human safety studies.
Want to Apply This Research?
- Users with family history of early heart disease could track arterial health markers (blood pressure, cholesterol levels, and inflammation markers like CRP) monthly through their healthcare provider, noting any changes as new LIPA-targeting treatments become available.
- While waiting for potential LIPA-targeting drugs, users should focus on proven heart disease prevention: maintain a heart-healthy diet low in saturated fat, exercise regularly, manage stress, and take prescribed cholesterol medications. Log these behaviors in the app to establish baseline health metrics.
- Set quarterly reminders to check lipid panel results and blood pressure. Track these metrics in the app alongside lifestyle factors. As LIPA research advances toward human trials, users can use the app to monitor for clinical trial opportunities and stay informed about new treatment options.
This research describes laboratory findings in mice and does not represent approved human treatments. LIPA-targeting therapies are not currently available for clinical use. Individuals concerned about heart disease risk should consult with their healthcare provider about proven prevention strategies including diet, exercise, and medications. This article is for educational purposes and should not be interpreted as medical advice. Always discuss genetic risk factors and new research with a qualified cardiologist or physician before making health decisions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.